Phase 2

Completed

NCT05225675

Empasiprubart (ARGX-117)

View on ClinicalTrials.gov ↗

Timeline

Study Dates

Start Date

—

Est. Completion

—

Enrollment Target

—

Status

Completed

Study Design

Primary Endpoint

Safety, tolerability, efficacy, PK/PD, immunogenicity of 2 ARGX-117 dose regimens

Registry

ClinicalTrials.gov Record

Registry ID

NCT05225675

Direct Link

clinicaltrials.gov/NCT05225675 ↗

Related Treatment

Treatment Being Studied

Empasiprubart (ARGX-117) →